Key stakeholders’ perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa

By sjmartinez • March 24, 2023

Beesham I, Milford C, Joseph Davey DL, Smit J, Mansoor LE, Beksinska M. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa. Afr J AIDS Res. 2023 Mar 23:1-9. doi: 10.2989/16085906.2023.2169177. Epub ahead of print. PMID: 36951406.

Tags: HIV prevention options, Infectious Diseases, post-trial access, PrEP, Publications, standard of prevention

Factors associated with cervical cancer screening: results from cross-sectional surveys in Kenya and Malawi

Moucheraud C, Chibaka S, Golub G, Kalande P, Makwaya A, Ochieng E, Ogutu V, Phiri K, Phiri S, Hoffman RM. Factors associated with cervical cancer[...]

Risks for sudden cardiac and undetermined cause of death among people with HIV in the reprieve primary cardiovascular prevention trial

deFilippi C, Awwad A, Bloomfield GS, Weir IR, Ribaudo H, Zanni MV, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Diggs MR, Chu SM, Paradis K, MacArthur[...]

rLVS(delta) capB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

Jia Q, Bowen RA, Masleša-Galić S, Horwitz MA. rLVS ΔcapB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal[...]